Tivantinib for advanced hepatocellular carcinoma: is MET still a viable target?
Mené sur 340 patients atteints d'un carcinome hépatocellulaire de stade avancé surexprimant MET, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du tivantinib, un inhibiteur de MET dispensé par voie orale en traitement de deuxième ligne (durée médiane de suivi : 18,1 mois)
The HGF-MET receptor pathway represents an attractive therapeutic target for hepatocellular carcinoma because of its crucial role in hepatocellular carcinoma development. Tivantinib, a putative MET inhibitor, did not improve overall survival compared with placebo in the METIV-HCC study, as reported in the Lancet Oncology by Lorenza Rimassa and colleagues,1 potentially casting doubt on the role of MET inhibition as a viable therapeutic strategy for patients with hepatocellular carcinoma. METIV-HCC was a randomised, double-blind, placebo-controlled, phase 3 trial of oral tivantinib (120 mg twice daily) compared with placebo in patients with advanced hepatocellular tumours with high MET-expression (staining intensity score of ≥2 in ≥50% of tumour cells) who had disease progression after previous sorafenib therapy.
The Lancet Oncology , commentaire, 2017